FDA granted Mylan Pharmeceuticals, now Viatris, approval for the first generic of AstraZeneca’s symbicort (budesonide and formoterol fumarate dihydrate) inhalation aerosol for the treatment of asthma in patients six years of age and older and the maintenance treatment of airflow obstruction and reducing exacerbations for patients with chronic obstructive pulmonary disease COPD, including chronic bronchitis and/or emphysema.
- NOTE: Dec. 2021,
Viatris Bid to Sell Generic of Astra’s Symbicort Gets New Life
NOTE
- Viatris Inc. rose 1.5% to $9.96 as of 3:51 p.m. New York time
- 11 holds, 5 buys, 0 sells
To view the source of this information, click
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.